Clinical Trial Update: Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects [Phase 1]

View source ↗

Summary

Phase 1 study characterizes the pharmacokinetics of aprepitant in HIV-infected subjects and explores potential anti-inflammatory effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: University of Pennsylvania | Conditions: HIV Infection | Phase 1 | Status: COMPLETED